Registered title, quoted from ClinicalTrials.gov
Pucotenlimab and Anlotinib in Combination With Chemotherapy
An open trial on breast cancer, registered on ClinicalTrials.gov. Led by Zhejiang Cancer Hospital; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07896668, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 8
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (8 points)Hide the checklist
18 years to Not stated; sex: all
Registered eligibility fields
Histologically confirmed invasive breast carcinoma with documented ER-negative, PR-negative, and HER2-negative status, defined as:
Inclusion criterion 3
Clinical stage II-III per AJCC 8th edition and at least one measurable lesion per RECIST v1.1.
Inclusion criterion 8
NYHA class < 3;
Inclusion criterion 19
**Female patients**: surgically sterile, postmenopausal, or agree to use at least one medically approved contraceptive measure (e.g., IUD, oral contraceptives, condoms) during and for 6 months after the treatment period; negative serum/urine pregnancy test within 7 days prior to enrollment; not lactating.
Inclusion criterion 23
**Male patients**: agree to use at least one medically approved contraceptive measure (e.g., condom, abstinence) during and for 6 months after the treatment period.
Inclusion criterion 24
ECOG performance status 0-1.
Inclusion criterion 10
Absolute neutrophil count ≥ 1.5 × 10⁹/L;
Inclusion criterion 12
Platelet count ≥ 100 × 10⁹/L;
Inclusion criterion 13
Hemoglobin ≥ 90 g/L;
Inclusion criterion 14
Total bilirubin ≤ 1.5 × ULN;
Inclusion criterion 15
AST, ALT, and ALP ≤ 2.5 × ULN;
Inclusion criterion 16
Serum creatinine ≤ 1.5 × ULN or creatinine clearance (Cockcroft-Gault formula) ≥ 50 mL/min.
Inclusion criterion 17
History of invasive malignancy ≤ 5 years prior to informed consent, except adequately treated basal/squamous cell skin cancer or in situ cervical cancer.
Exclusion criterion 2
HBV carriers or patients stabilized on antiviral therapy with HBV DNA ≤ 500 IU/mL or < 2500 copies/mL are allowed.
Exclusion criterion 13
Active hepatitis C defined as positive anti-HCV antibody with quantifiable HCV RNA above the lower limit of detection.
Exclusion criterion 14
HIV positive;
Exclusion criterion 16
Pregnant or lactating female patients.
Exclusion criterion 11
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: scans and measurable lesions.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07896668, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Voluntary participation and signed informed consent.
- Age ≥ 18 years, male or female.
- Histologically confirmed invasive breast carcinoma with documented ER-negative, PR-negative, and HER2-negative status, defined as:
- ER and PR: nuclear staining < 10% by IHC;
- HER2: 0 or 1+ by IHC, or 2+ with negative FISH amplification.
- Known PD-L1 status.
- Assessed by breast surgeon as eligible and planned for radical mastectomy.
- Clinical stage II-III per AJCC 8th edition and at least one measurable lesion per RECIST v1.1.
- No prior systemic therapy for the current disease, including surgery, radiotherapy, chemo/immunotherapy, etc.
- ECOG performance status 0-1.
- Adequate hematologic and organ function, as defined by:
- Absolute neutrophil count ≥ 1.5 × 10⁹/L;
- Platelet count ≥ 100 × 10⁹/L;
- Hemoglobin ≥ 90 g/L;
- Total bilirubin ≤ 1.5 × ULN;
- AST, ALT, and ALP ≤ 2.5 × ULN;
- Serum creatinine ≤ 1.5 × ULN or creatinine clearance (Cockcroft-Gault formula) ≥ 50 mL/min.
- Adequate cardiac function:
- NYHA class < 3;
- Left ventricular ejection fraction (LVEF) ≥ 50%.
- Life expectancy ≥ 3 months.
- Contraceptive requirements:
- **Female patients**: surgically sterile, postmenopausal, or agree to use at least one medically approved contraceptive measure (e.g., IUD, oral contraceptives, condoms) during and for 6 months after the treatment period; negative serum/urine pregnancy test within 7 days prior to enrollment; not lactating.
- **Male patients**: agree to use at least one medically approved contraceptive measure (e.g., condom, abstinence) during and for 6 months after the treatment period.
- Willing and able to comply with study visits, procedures, prohibitions, and restrictions specified in the protocol.
Exclusion Criteria:
- Stage IV (metastatic) TNBC.
- History of invasive malignancy ≤ 5 years prior to informed consent, except adequately treated basal/squamous cell skin cancer or in situ cervical cancer.
- Prior systemic anticancer therapy (including investigational agents) before planned start of study treatment.
- Known hypersensitivity to pucotenlimab, nab-paclitaxel, or any of their components.
- Active or history of autoimmune disease with potential for relapse (e.g., SLE, rheumatoid arthritis, inflammatory bowel disease, autoimmune thyroid disease, multiple sclerosis, vasculitis, glomerulonephritis) or high risk (e.g., organ transplant requiring immunosuppressive therapy). **Exceptions allowed for**:
- Type I diabetes mellitus stabilized on fixed insulin regimen;
- Autoimmune hypothyroidism on hormone replacement therapy only;
- Skin conditions not requiring systemic therapy (e.g., eczema, rash involving < 10% BSA, psoriasis without ocular symptoms).
- Major surgery, open biopsy, or significant trauma within 4 weeks prior to planned start of study treatment. Major surgery defined as requiring at least 3 weeks of recovery before study treatment.
- History of allogeneic organ or hematopoietic stem cell transplantation.
- Pregnant or lactating female patients.
- Untreated acute/chronic active hepatitis B or hepatitis C infection. **Exceptions**:
- HBV carriers or patients stabilized on antiviral therapy with HBV DNA ≤ 500 IU/mL or < 2500 copies/mL are allowed.
- Active hepatitis C defined as positive anti-HCV antibody with quantifiable HCV RNA above the lower limit of detection.
- Uncontrolled concurrent illness, including but not limited to:
- HIV positive;
- Active or poorly controlled severe infection;
- Severe or uncontrolled systemic disease (e.g., severe psychiatric/neurological disorders, epilepsy/dementia, unstable or uncompensated respiratory, cardiovascular, hepatic, or renal disease);
- Unstable systemic disease such as diabetes (fasting glucose ≥ 10 mmol/L) or hypertension (systolic BP > 150 mmHg or diastolic BP > 90 mmHg).
- Active bleeding or new thrombotic disease on therapeutic anticoagulation, or bleeding diathesis.
- Active tuberculosis.
- Any other condition that, in the investigator's judgment, makes the patient unsuitable for participation.
Quoted from ClinicalTrials.gov, NCT07896668, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07896668, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.